Modelling the immunological response to a tetravalent dengue vaccine from multiple phase-2 trials in Latin America and South East Asia

Vaccine

Volumn 33, Issue 31, 2015, Pages 3746-3751

  Dorigatti, Ilaria ^a   Aguas, Ricardo ^a   Donnelly, Christl A ^a   Guy, Bruno ^b   Coudeville, Laurent ^b   Jackson, Nicholas ^b   Saville, Melanie ^b   Ferguson, Neil M ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b SANOFI PASTEUR   (France)

Author keywords

CYD TDV dengue vaccine; Multivariate regression; PRNT50 antibody titres; Serotype interactions

Indexed keywords

CYD TETRAVALENT DENGUE VACCINE; DENGUE VACCINE; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; CYD-TDV VACCINE; VIRUS ANTIBODY;

ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BRAZIL; CHILD; DENGUE VIRUS 1; DENGUE VIRUS 2; DENGUE VIRUS 3; DENGUE VIRUS 4; FEMALE; HUMAN; IMMUNOGENICITY; MAJOR CLINICAL STUDY; MALE; PHASE 2 CLINICAL TRIAL (TOPIC); PHILIPPINES; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SOUTH AND CENTRAL AMERICA; THAILAND; VIET NAM; ADOLESCENT; ADULT; BLOOD; DENGUE VIRUS; IMMUNOLOGY; INFANT; PRESCHOOL CHILD; SOUTHEAST ASIA; STATISTICAL MODEL; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIBODIES, VIRAL; ASIA, SOUTHEASTERN; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS, PHASE II AS TOPIC; DENGUE VACCINES; DENGUE VIRUS; FEMALE; HUMANS; INFANT; LATIN AMERICA; MALE; MODELS, STATISTICAL; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84937642156     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.05.059     Document Type: Article

References (31)

1. Bhatt S., Gething P.W., Brady O.J., et al. The global distribution and burden of dengue. Nature 2013, 496:504-507.
2. Thomas S.J., Endy T.P. Critical issues in dengue vaccine development. Curr Opin Infect Dis 2011, 24(5):442-450.
3. Murrell S., Wu S.C., Butler M. Review of dengue virus and the development of a vaccine. Biotechnol Adv 2011, 29(2):239-247.
4. Walker T., Johnson P.H., Moreira L.A., et al. The wMel Wolbachia strain blocks dengue and invades caged Aedes aegypti populations. Nature 2011, 476(7361):450-453.
5. Hoffmann A.A., Montgomery B.L., Popovici J., et al. Successful establishment of Wolbachia in Aedes populations to suppress dengue transmission. Nature 2011, 476(7361):454-457.
6. Tran N.H., Luong C.Q., Vu T.Q.H., et al. Safety and immunogenicity of recombinant, live attenuated tetravalent dengue vaccine (CYD-TDV) in healthy Vietnamese adults and children. J Vaccines Vaccin 2012, 3:162.
7. Leo Y.S., Wilder-Smith A., Archuleta S., et al. Immunogenicity and safety of recombinant tetravalent dengue vaccine (CYD-TDV) in individuals aged 2-45 years: Phase II randomized controlled trial in Singapore. Hum Vaccin Immunother 2012, 8(9):1259-1271.
8. Lanata C.F., Andrade T., Gil A., et al. Immunogenicity and safety of tetravalent dengue vaccine in 2-11 year-olds previously vaccinated against yellow fever: randomized, controlled, phase II study in Piura, Peru. Vaccine 2012, 30(41):5935-5941.
9. Sabchareon A., Wallace D., Sirivichayakul C., et al. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet 2012, 380(9853):1559-1567.
10. Crevat D., Brion J.D., Gailhardou S., Laot T.M., Capeding M.R. First experience of concomitant vaccination against dengue and MMR in toddlers. Pediatr Infect Dis J 2015 May, 8. (Epub ahead of print).
11. Dayan G.H., Garbes P., Noriega F., et al. Immunogenicity and safety of a recombinant tetravalent dengue vaccine in children and adolescents ages 9-16 years in Brazil. Am J Trop Med Hyg 2013, 89(6):1058-1065.
12. Villar L.Á., Rivera-Medina D.M., Arredondo-García J.L., et al. Safety and immunogenicity of a recombinant tetravalent dengue vaccine in 9-16 year olds: a randomized, controlled, phase II trial in Latin America. Pediatr Infect Dis J 2013, 32(10):1102-1109.
13. Timiryasova T.M., Bonaparte M.I., Luo P., Zedar R., Hu B.T., Hildreth S.W. Optimization and validation of a plaque reduction neutralization test for the detection of neutralizing antibodies to four serotypes of dengue virus used in support of dengue vaccine development. Am J Trop Med Hyg 2013, 88(5):962-970.
14. Endy T.P., Nisalak A., Chunsuttitwat S., et al. Relationship of preexisiting dengue virus (DV) neutralizing antibody levels to viremia and severity of disease in a prospective cohort study of DV infection in Thailand. J Infect Dis 2004, 189(6):990-1000.
15. Burnham K.P., Anderson D.R. Model selection and multimodel inference: a practical information-theoretic approach 2002, Springer. 2nd ed.
16. Johnson R.A., Wichern D.W. Applied multivariate statistical analysis 1988, Prentice-Hall. 2nd ed.
17. Thomas S.J., Nisalak A., Anderson K.B., et al. Dengue plaque reduction neutralization test (PRNT) in primary and secondary dengue virus infections: how alterations in assay conditions impact performance. Am J Trop Med Hyg 2009, 81(5):825-833.
18. Rainwater-Lovett K., Rodriguez-Barraquer I., Cummings D.A.T., Lessler J. Variation in dengue virus plaque reduction neutralization testing: systematic review and pooled analysis. BMC Infect Dis 2012, 12(1):233.
19. Salje H., Rodríguez-Barraquer I., Rainwater-Lovett I., et al. Variability in dengue titer estimates from plaque reduction neutralization tests poses a challenge to epidemiological studies and vaccine development 2014, 8(6):e2952.
20. Yen N.T., Duffy M.R., Hong N.M., Hien N.T., Fischer M., Hills S.L. Surveillance for Japanese encephalitis in Vietnam, 1998-2007. Am J Trop Med Hyg 2010, 83(4):816-819.
21. Scott R.M., Eckels K.H., Bancroft W.H., Summers P.L., McCown J.M., Anderson J.H., et al. Dengue 2 vaccine: dose response in volunteers in relation to yellow fever immune status. J Infect Dis 1983, 148(6):1055-1060.
22. Schlesinger R.W., Gordon I., Frankel J.W., Winter J.W., Patterson P.R., Dorrance W.R. Clinical and serologic response of man to immunization with attenuated dengue and yellow fever viruses. J Immunol 1956, 77(5):352-364.
23. Guirakhoo F., Kitchener S., Morrison D., et al. Live attenuated chimeric yellow fever dengue type 2 (chimerivax-den2) vaccine: phase I clinical trial for safety and immunogenicity. Hum Vaccin 2006, 2:60-67. (Research paper).
24. Guy B., Barban V., Mantel N., et al. Evaluation of interferences between dengue vaccine serotypes in a monkey model. Am J Trop Med Hyg 2009, 80(2):302-311.
25. Poo J., Galan F., Forrat R., Zambrano B., Lang J., Dayan G.H. Live-attenuated tetravalent dengue vaccine in dengue-naïve children, adolescents, and adults in Mexico City: randomized controlled phase 1 trial of safety and immunogenicity. Pediatr Infect Dis J 2011, 30(1):e9-e17.
26. Qiao M., Shaw D., Forrat R., Wartel-Tram A., Lang J. Priming effect of dengue and yellow fever vaccination on the immunogenicity, infectivity, and safety of a tetravalent dengue vaccine in humans. Am J Trop Med Hyg 2011, 85(4):724-731.
27. Dayan G.H., Galan-Herrera J., Forrat R., et al. Assessment of bivalent and tetravalent dengue vaccine formulations in flavirvirus-naïve adults in Mexico. Hum Vaccin Immunother 2014, 10(10):2853-2863.
28. Morrison D., Legg T.J., Billings C.W., Forrat R., Yoksan S., Lang J. A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults. J Infect Dis 2010, 201(3):370-377.
29. Sanofi Pasteur The world's first, large-scale dengue vaccine efficacy study successfully achieved its primary clinical endpoint April 2014, (Accessed on 29 May 2014). Available from http://sanofipasteur.com/en/Documents/PDF/PR/Dengue-ENG.pdf (Press Release).
30. Capeding M.R., Tran N.H., Hadinegoro S.R.S., et al. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet 2014, 384(9951):1358-1365.
31. Villar L., Dayan G.H., Arredondo-Garcia J.L., et al. Efficacy of a tetravalent dengue vaccine in children in Latin America. N Engl J Med 2015, 372:113-123.